PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S. Adenoidectomy and Tonsillectomy...

Transcription

1 CHAPTER ONE: INTRODUCTION... 1 STUDY GOAL AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS... 3 RELATED BCC PUBLICATIONS... 3 BCC ONLINE SERVICES... 3 DISCLAIMER... 3 CHAPTER TWO: SUMMARY... 4 PROJECTED GROWTH OF PEDIATRIC MARKETS... 4 SUMMARY TABLE GLOBAL TRENDS IN PEDIATRIC HEALTH CARE, THROUGH 2013 ($ MILLIONS)... 4 SUMMARY FIGURE GLOBAL TRENDS IN PEDIATRIC HEALTH CARE, BASED ON CONDITION, ($ MILLIONS)... 5 MARKET FORECASTS FOR SHORT-TERM ILLNESSES... 5 ROTAVIRUS... 5 EAR INFECTIONS... 6 UPPER RESPIRATORY INFECTIONS... 6 MARKET FORECASTS FOR CHRONIC ILLNESSES... 6 ALLERGIES... 6 ATTENTION DEFICIT DISORDERS... 7 ASTHMA... 7 AUTISM SPECTRUM DISORDERS... 7 DIABETES... 8 OBESITY... 8 CHAPTER THREE: OVERVIEW OF THE PEDIATRIC HEALTHCARE INDUSTRY... 9 TABLE 1 PROJECTED PEDIATRIC PREVENTATIVE CARE COSTS FROM BIRTH THROUGH AGE 18 IN THE U.S., THROUGH 2013 ($ MILLIONS)... 9 PRENATAL CARE/IMPLICATIONS... 9 INTERNATIONAL PRENATAL CARE/IMPLICATIONS Low Birth Weight NEWBORN CARE CARE IN THE U.S INTERNATIONAL NEWBORN CARE Malnutrition CHILDREN AGE 1 TO CHILDREN AGE 7 TO ADOLESCENT CHILDREN AGE 13 TO

2 ADOLESCENT REPRODUCTIVE HEALTH SEXUALLY TRANSMITTED DISEASES Human papillomavirus (HPV) VACCINES/IMMUNIZATIONS TABLE 2 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS TABLE 3 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6 YEARS TABLE 4 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO TABLE 4 (CONTINUED) VACCINE EFFICACY AND CONTROVERSY IMPLICATIONS FOR FUTURE DEVELOPMENTS IN THE U.S IMPLICATIONS FOR FUTURE (CONTINUED) CHAPTER FOUR: SHORT-TERM ILLNESSES IN THE PEDIATRIC POPULATION TABLE 5 GLOBAL COSTS OF THREE PRIMARY SHORT-TERM ILLNESSES IN PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) FIGURE 1 GLOBAL COST OF PEDIATRIC SHORT-TERM ILLNESS, 2008 AND 2013 ($ MILLIONS) OTITIS MEDIA (EAR INFECTIONS) CAUSES OF OTITIS MEDIA Allergies Infection Blockage Nutrition and breastfeeding TYPES AND SYMPTOMS TREATMENT Pharmacological intervention Use of Prevnar TABLE 6 GLOBAL PRESCRIPTION COSTS FOR TREATMENT OF PEDIATRIC OTITIS MEDIA, THROUGH 2013 ($ MILLIONS) TABLE 7 PRESCRIPTION COSTS FOR TREATMENT OF PEDIATRIC OTITIS MEDIA, IN THE U.S., THROUGH 2013 ($ MILLIONS) Surgical Intervention Myringotomy TABLE 8 GLOBAL SURGICAL COSTS FOR MYRINGOTOMY IN PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S. PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) Adenoidectomy and Tonsillectomy... 26

3 TABLE 10 GLOBAL SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 11 SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN U.S. PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) GASTROINTESTINAL ILLNESSES ROTAVIRUS Transmission Symptoms Treatment Dehydration Zinc Vaccinations Rotateq Rotarix TABLE 12 GLOBAL VACCINATION FOR PEDIATRIC ROTOVIRUS, THROUGH 2013 ($ MILLIONS) TABLE 13 U.S. VACCINATION FOR PEDIATRIC ROTOVIRUS, THROUGH 2013 ($ MILLIONS) GASTROESOPHAGEAL REFLUX Treatment Eliminate symptoms Heal esophagus Prevent complications TABLE 14 CURRENT TREATMENTS FOR GERD UPPER RESPIRATORY INFECTIONS TABLE 15 GLOBAL DIRECT COSTS OF PEDIATRIC UPPER RESPIRATORY INFECTIONS, THROUGH 2013 ($ MILLIONS) TABLE 16 DIRECT COSTS FOR PEDIATRIC UPPER RESPIRATORY INFECTIONS IN THE U.S, THROUGH 2013 ($ MILLIONS) CAUSES AND SYMPTOMS TABLE 17 COMMON SYMPTOMS OF AN URI TABLE 17 (CONTINUED) TREATMENTS Increased Fluid Intake Second-hand Smoke Medications ANTIBIOTIC TREATMENTS Withdrawing Medicines COMPLICATIONS CHAPTER FIVE: CHRONIC ILLNESSES IN THE PEDIATRIC POPULATION... 39

4 TABLE 18 GLOBAL COST OF CHRONIC ILLNESSES IN THE PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) TABLE 19 COST OF CHRONIC ILLNESSES IN U.S. PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) FIGURE 2 PROJECTED COSTS FOR PEDIATRIC CHRONIC ILLNESSES IN THE U.S., THROUGH 2013 ($ MILLIONS) CYSTIC FIBROSIS ORIGINS OF THE DISEASE DIAGNOSING CF PREVALENCE TREATMENT Oscillating Positive Expiratory Pressure (PEP) High-Frequency Chest Wall Oscillation (HFCWO) Medications Pulmozyme TOBI Enzyme Treatments TABLE 20 GLOBAL SALES FOR PEDIATRIC CYSTIC FIBROSIS MEDICATIONS AND THERAPIES, THROUGH 2013 ($ MILLIONS) TABLE 21 U.S. SALES FOR PEDIATRIC CYSTIC FIBROSIS MEDICATIONS AND THERAPIES, THROUGH 2013 ($ MILLIONS) TABLE 22 U.S. SALES FOR CYSTIC FIBROSIS MEDICATIONS, BY COMPANY, THROUGH 2013 ($ MILLIONS) Antibiotics DIABETES HISTORY ORIGINS OF THE DISEASE TYPE 1 DIABETES TYPE 2 DIABETES COMPLICATIONS Hypoglycemia Hyperglycemia Ketoacidosis DIAGNOSING DIABETES Type 1 Diagnosis Type 2 Diagnosis Prediabetes PREVALENCE COMPLICATIONS OF PEDIATRIC DIABETES Growth Psychological Characteristics Health Status Family Dynamics Outside Care... 52

5 TREATMENTS Glycemic Control Types of Insulin Long-Acting Insulins Rapid Insulins Intermediate-Acting Insulin Short-Acting Insulin ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES Alternative Delivery Options Insulin Pump Insulin Pens Inhaled Insulin TABLE 23 GLOBAL INSULIN MARKET, THROUGH 2013 ($ MILLIONS) TABLE 24 INSULIN MARKET IN U.S., THROUGH 2013 ($ MILLIONS) TABLE 25 INSULIN APPROVED FOR CHILDREN AND ADOLESCENTS IN THE U.S TABLE 26 GLOBAL PEDIATRIC INSULIN MARKET, THROUGH 2013 ($ MILLIONS) TABLE 27 PEDIATRIC INSULIN MARKET IN U.S., THROUGH 2013 ($ MILLIONS) ORAL AGENTS TABLE 28 SELECTED LIST OF MOST COMMONLY PRESCRIBED ORAL AGENTS TABLE 28 (CONTINUED) NUTRITIONAL MANAGEMENT PHYSICAL ACTIVITY GLUCOSE MONITORING SYSTEMS TABLE 29 SELECTED LIST OF COMPANIES MARKETING GLUCOSE MONITORING TESTS Abbott Laboratories New Technology TABLE 30 WORLDWIDE MARKET FOR BLOOD GLUCOSE MONITORING DEVICES, THROUGH 2013 ($ MILLIONS) TABLE 31 U.S. BLOOD GLUCOSE MONITORING MARKET, THROUGH 2013 ($ MILLIONS) TABLE 32 SELECTED GLOBAL BLOOD GLUCOSE MONITORING MARKET BY COMPANY, THROUGH 2013 ($ MILLIONS) Pediatric Market TABLE 33 GLOBAL PEDIATRIC BLOOD GLUCOSE MONITORING MARKET, THROUGH 2013 ($ MILLIONS) TABLE 34 U.S. PEDIATRIC BLOOD GLUCOSE MONITORING MARKET, THROUGH 2013 ($ MILLIONS) LOW-BIRTH WEIGHT ORIGINS OF THE DISEASE... 64

6 PREVALENCE Consequences in the U.S Neurological Problems Chronic Lung Disease Hearing Loss Retinopathy of Prematurity DIAGNOSING LOW BIRTH WEIGHT TREATMENT FOR LOW BIRTH WEIGHT Retinopathy COSTS OF LOW BIRTH-WEIGHT CHILDREN MALNUTRITION ORIGINS OF THE DISEASE DIAGNOSING MALNUTRITION MICRONUTRIENT DEFICIENCIES TABLE 35 EFFECTS OF MICRONUTRIENT DEFICIENCIES Vitamin A Deficiency Iron Deficiency Iodine Deficiency Folic Acid PREVALENCE TREATMENTS ADDRESSING MALNUTRITION IN THE U.S Successful National Nutrition Programs Supplemental Nutrition Assistance Program (SNAP) Women, Infants and Children (WIC) ADDRESSING MALNUTRITION GLOBALLY Nutriset TABLE 36 PROJECTED SALES OF PLUMPY NUT, THROUGH 2013 ($ MILLIONS) NEUROLOGICAL DISORDERS ATTENTION DEFICIT DISORDER/ATTENTION DEFICIT HYPERACTIVITY DISORDER ORIGINS OF ADHD Brain Structures and Chemicals Genetic Factors Dietary Factors PREVALENCE DIAGNOSING ATTENTION DEFICIT/ATTENTION DEFICIT/HYPERACTIVITY DISORDERS TABLE 37 COMMON SYMPTOMS OF ADHD OTHER DISORDERS TABLE 38 ADDITIONAL DISORDERS SEEN IN CHILDREN WITH ADHD... 80

7 TREATMENT TYPES Therapy Pharmaceutical Treatments Psychostimulant Medication Non-stimulant Medication Antidepressant/Antianxiety Medications Antipsychotic Medication Mood Stabilizing Medication TABLE 39 SELECTED PRESCRIPTION MEDICATIONS FOR TREATING ADHD TABLE 39 (CONTINUED) TABLE 40 PRESCRIPTION MEDICATIONS FOR TREATING ADHD, IN CHILDREN UNDER AGE TABLE 40 (CONTINUED) Global Market for ADHD Treatments TABLE 41 GLOBAL MARKET FOR PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 ($ MLLIONS) TABLE 42 GLOBAL MARKET FOR PEDIATRIC PRESCRIPTION ADHD MEDICATION, THROUGH U.S. Market for ADHD Treatments TABLE 43 U.S. MARKET FOR PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 44 U.S. MARKET FOR PEDIATRIC PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 ($ MILLIONS) AUTISM SPECTRUM DISORDERS AUTISM TABLE 45 SYMPTOMS OF AUTISM ASPERGER S DISORDER CHILDHOOD DISINTEGRATIVE DISORDER RETT S SYNDROME PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED ORIGINS OF AUTISM SPECTRUM DISORDERS Genetics Rejected Origins of Autism Spectrum Disorders Environmental Factors PREVALENCE DIAGNOSING ASD TREATMENT FOR ASD Psychoeducational Treatment Medical Treatment Dietary Changes Vitamin Therapy Risperidone... 92

8 ECONOMIC IMPACT OF AUTISM TABLE 46 GLOBAL DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 47 GLOBAL DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATIONS IN THE PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) TABLE 48 U.S. DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATION IN PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) CEREBRAL PALSY ORIGINS OF THE DISORDER DIAGNOSING CEREBRAL PALSY PREVALENCE OF CP TABLE 49 U.S. AVERAGE LIFETIME CEREBRAL PALSY COSTS PER PERSON, THROUGH 2013 ($ MILLIONS) TABLE 50 GLOBAL AVERAGE COSTS FOR PEDIATRIC CP PATIENTS UP TO AGE 18, THROUGH 2013 ($ MILLIONS) TABLE 51 U.S. AVERAGE COSTS FOR PEDIATRIC CP PATIENTS UPTO AGE 18, THROUGH 2013 ($ MILLIONS) TREATMENT OF CEREBRAL PALSY Therapies Surgical Procedures Medications TABLE 52 MEDICATIONS FOR CP PATIENTS Magnesium Sulfate DEPRESSION ORIGINS OF THE DISEASE Genetic Factors Biological Factors Sociological Factors Psychological Factors Risk Factors for Depression Gender Age Marital status Family History Parental Deprivation Social Support Family Type Types of Depression PREVALANCE OF THE DISORDER DIAGNOSING DEPRESSION TABLE 53 SYMPTOMS OF DEPRESSION TREATMENT FOR DEPRESSION

9 TABLE 54 GLOBAL DIRECT AND INDIRECT COST OF DEPRESSION, THROUGH 2013 ($ BILLIONS) Therapy Antidepressant Medications TABLE 55 ANTIDEPRESSANT MEDICATIONS APPROPRIATE FOR PEDIATRIC PATIENTS Government Warnings TABLE 56 GLOBAL COST OF ANTIDEPRESSANT MEDICATIONS IN PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) TABLE 57 COST OF ANTIDEPRESSANT MEDICATION IN THE U.S. PEDIATRIC POPULATION, THROUGH 2013 ($ MILLIONS) EPILEPSY/SEIZURES ORIGINS OF THE DISEASE Inherited Genetic Causes Congenital Causes Acquired TABLE 58 POTENTIAL CAUSES OF EPILEPSY, BY AGE DIAGNOSING EPILEPSY TABLE 59 INTERNATIONAL CLASSIFICATION OF EPILEPTIC SEIZURES PREVALENCE TREATMENTS Anti-epileptic Medications TABLE 60 SELECTED CURRENT MEDICATIONS FOR EPILEPSY TABLE 61 PROJECTED GLOBAL DIRECT COSTS OF EPILEPSY MEDIATIONS, THROUGH 2013 ($ MILLIONS) TABLE 62 PROJECTED GLOBAL PEDIATRIC DIRECT COSTS OF EPILEPSY MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 63 PROJECTED U.S. DIRECT COSTS OF EPILEPSY, THROUGH 2013 ($ MILLIONS) TABLE 64 PROJECTED DIRECT COSTS FOR THE U.S. PEDIATRIC EPILEPSY POPULATION, THROUGH 2013 ($ MILLIONS) Vagus Nerve Stimulation Surgical Options The Future OBESITY TABLE 65 PROJECTED U.S. PEDIATRIC DIRECT HEALTHCARE COSTS ATTRIBUTABLE TO OVERWEIGHT AND OBESITY, THROUGH 2013 ($ MILLIONS) ORIGINS OF THE DISEASE DIAGNOSING OBESITY Genetic Factors Environmental Factors Behavioral Factors

10 PREVALENCE OF THE DISEASE TREATMENT OF OBESITY Healthy Food Choices Dietary Restrictions Increased Exercise Pharmaceutical Products for Adolescents TABLE 66 GLOBAL MARKET FOR PRESCRIPTION WEIGHT LOSS PRODUCTS THROUGH 2013 ($ MILLIONS) TABLE 67 GLOBAL MARKET FOR PRESCRIPTION WEIGHT LOSS PRODUCTS FOR ADOLESCENTS, THROUGH 2013 ($ MILLIONS) TABLE 68 U.S MARKET FOR PRESCRIPTION WEIGHT LOSS PRODUCTS FOR ADOLESCENTS, THROUGH 2013 ($ MILLIONS) Surgical Options TABLE 69 RECOMMENDED CRITERIA FOR BARIATRIC SURGERY FOR ADOLESCENTS TABLE 70 GLOBAL MARKET FOR SURGICAL PROCEDURESFOR PEDIATRIC PATIENTS WHO ARE OBESE/OVERWEIGHT, THROUGH 2013 ($ MILLIONS) TABLE 71 MARKET FOR SURGICAL PROCEDURES FOR U.S. PEDIATRIC PATIENTS WHO ARE OBESE/OVERWEIGHT, THROUGH 2013 ($ MILLIONS) Complications GLOBAL TRENDS TABLE 72 PROJECTED GLOBAL PEDIATRIC DIRECT HEALTHCARE COSTS ATTRIBUTABLE TO OVERWEIGHT AND OBESITY ($ MILLIONS) RESPIRATORY ILLNESSES ALLERGIES ORIGINS OF THE DISEASE Airborne Allergies Food Allergies TABLE 73 COMMON FOOD ALLERGENS Sinusitis Drug Allergy Allergic Rhinitis Diagnosing Breathing Allergies Prevalence of Allergic Rhinitis TREATMENT Immunotherapy Environmental Measures Antihistamines Cetirizine Fexofenadine Desloratadine

11 Loratadine Mast Cell Stabilizers Anti-IgE Antibody TABLE 74 COMMON ALLERGY MEDICATIONS APPROPRIATE FOR CHILDREN TABLE 74 (CONTINUED) COSTS TABLE 75 GLOBAL DIRECT COSTS OF ALLERGIES, THROUGH 2013 ($ MILLIONS) TABLE 76 DIRECT COSTS OF ALLERGIES IN THE U.S., THROUGH 2013 ($ MILLIONS) TABLE 77 GLOBAL DIRECT COSTS OF PEDIATRIC ALLERGIES, THROUGH 2013 ($ MILLIONS) TABLE 78 DIRECT COSTS OF U.S. PEDIATRIC ALLERGIES, THROUGH 2013 ($ MILLIONS) ASTHMA ORIGINS OF THE DISEASE DIAGNOSING ASTHMA Exercise Infections Allergies Irritants Weather Emotions PREVALENCE OF ASTHMA TREATMENTS TABLE 79 FOUR-STEP GUIDELINES FOR TREATING ASTHMA IN CHILDREN UNDER THE AGE OF FIVE TABLE 80 FOUR-STEP GUIDELINES FOR TREATING ASTHMA IN CHILDREN OVER THE AGE OF FIVE TABLE 81 QUICK-ACTING MEDICATIONS FOR ASTHMA Inhaled Corticosteroids TABLE 82 SELECTED LISTING OF INHALED CORTICOSTEROIDS COSTS TABLE 83 GLOBAL COSTS FOR ASTHMA MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 84 U.S. COSTS FOR ASTHMA MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 85 GLOBAL COSTS FOR PEDIATRIC ASTHMA MEDICATIONS, THROUGH 2013 ($ MILLIONS) TABLE 86 COSTS FOR PEDIATRIC ASTHMA MEDICATIONS IN THE U.S., THROUGH 2013 ($ MILLIONS) CHAPTER SIX: CURRENT RESEARCH ALLERGIES

12 SCHERING-PLOUGH Allergy immunotherapy ASTHMA TM GENENTECH Xolair Anti-IL ASTRAZENECA Medimmune Anti-IL13 MAb (CAT-354) Anti-IL9 MAb (MEDI 528) MAP PHARMACEUTICALS SCHERING-PLOUGH Nasal Inhaled Combinations Pleconaril ASTHMATX Bronchial Thermoplasty TOPIGEN PHARMACEUTICALS SYNAIRGEN VECTURA PLC ATTENTION DEFICIT/ATTENTION DEFICIT HYPERACTIVITY DISORDER SHIRE US Intuniv SOMERSET PHARMACEUTICALS Selegiline CEPHALON Modafinil CEREBRAL PALSY GENETIC CAUSES OF CP STEM CELL RESEARCH CYSTIC FIBROSIS GENE THERAPY Copernicus Therapeutics INFECTIONS Aradigm Corp ENZYME REPLACEMENT Altus Pharmaceuticals Eurand IMPROVED HYDRATION/SALT TRANSPORT Lantiobio, Inc Sucampo Pharmaceuticals Inspire Pharmaceuticals Pharmaxis

13 Gilead Sciences PROTEIN PRODUCTION PTC Therapeutics Vertex Pharmaceuticals INHALATION THERAPY Vectura PLC DEPRESSION FOREST LABORATORIES F Lexapro SANOFI AVENTIS Saredutant SEPRACOR SEP SEP DIABETES INHALATION INSULIN Generex Biotechnology Coromed, Inc Nastech Pharmaceuticals Mannkind Corporation MAP Pharmaceuticals Vectura PLC TRANSDERMAL INSULIN DELIVERY Dermasonics Medingo Vyteris BLOOD GLUCOSE MONITORING Abbott Laboratories LONGER-LASTING INSULINS Novo Nordisk FOREST LABORATORIES COMBINATION DRUG THERAPIES Novartis/Pfizer Gleevec/Sutent Merck Januvia/metformin ORAL DIABETIC AGENTS Generex Biotechnology EAR INFECTIONS EPILEPSY/SEIZURES UCB PHARMACEUTICALS Brivaracetam JOHNSON & JOHNSON

14 Carisbamate( RWJ ) DIOXY-D-GLUCOSE RESEARCH SEPRACOR Eslicarbanzepine acetate (BIA-2-093) SCHWARZ BIOSCIENCES Lacosamide JAZZ PHARMACEUTICALS JZP HUPERZINE A NEUROADJUVANTS NAX Propylisopropylacetamide (PID) MARINUS PHARMACEUTICALS Ganaxolone VALEANT PHARMACEUTICALS Retigabine TARO PHARMACEUTICALS T OBESITY DRUGS MARKETED FOR OTHER CONDITIONS OBESITY DRUG PIPELINE Sanofi Aventis Phytopharm Arena Pharma TM TM (Continued) CHAPTER SEVEN: COMPANY PROFILES TM PHARMA A/S BUSINESS OVERVIEW FINANCIAL OVERVIEW PRODUCTS ABBOTT LABORATORIES ABBOTT LABORATORIES FINANCIAL INFORMATION PRODUCTS ALTUS PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ARADIGM CORPORATION BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ARENA PHARMACEUTICALS

15 BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ASTRAZENECA PLC BUSINESS OVERVIEW FINANCIALS PRODUCTS AVONTEC GMBH BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS AXCAN PHARMA USA BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS BAYER AG (MILES-BAYER) BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CHIESI FARMACEUTICI S.P.A BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS COPERNICUS THERAPEUTICS, INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS COROMED, INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ELI LILLY BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS EURAND PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS GENENTECH INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS GENEREX BIOTECHNOLOGY

16 BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS GILEAD SCIENCES BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS GLAXOSMITHKLINE PLC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS INSPIRE PHARMACEUTICALS, INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS JOHNSON & JOHNSON BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS KALOBIOS PHARMACEUTICALS, INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS LANTIBIO, INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS MANNKIND CORP BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS MAP PHARMAEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS MERCK & CO INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS NOVARTIS AG BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS NOVO NORDISK

17 BUSINESS OVERVIEW FINANCIAL OVERVIEW PRODUCTS NUTRISET BUSINESS OVERVIEW FINANCIAL OVERVIEW PRODUCTS PFIZER BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS PHARMAXIS, LTD BUSINESS OVERVIEW FINANCIAL INFORMAITON PRODUCTS PHYTOPHARM, PLC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS PTC THERAPEUTICS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ROCHE PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SANOFI-AVENTIS BUSINESS OVERVIEW FIANANCIAL INFORMATION PRODUCTS SCHERING-PLOUGH BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SEPRACOR BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SHIRE U.S BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SOLVAY PHARMACEUTICALS

18 BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SUCAMPO PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS SYNAIRGEN PLC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS TOPIGEN PHARMACEUTICALS INC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS UCB PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS VECTURA GROUP PLC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS VERTEX PHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS WYETH BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS APPENDIX: SELECTED PEDIATRIC PRODUCTS BY ILLNESS TABLE 87 SELECTED PEDIATRIC PRODUCTS BY ILLNESS TABLE 87 (CONTINUED) TABLE 87 (CONTINUED) TABLE 87 (CONTINUED) TABLE 87 (CONTINUED) TABLE 87 (CONTINUED) TABLE 87 (CONTINUED)